LBPH - Longboard Pharmaceuticals GAAP EPS of -$0.67 misses by $0.13
- Longboard Pharmaceuticals press release ( NASDAQ: LBPH ): Q2 GAAP EPS of -$0.67 misses by $0.13 .
- Cash, cash equivalents and short-term investments were approximately $87.4 million. Cash position is expected to support operations into 2024 based on our current business plan.
For further details see:
Longboard Pharmaceuticals GAAP EPS of -$0.67 misses by $0.13